90004-93-6 Usage
General Description
2'-Bromo-4'-nitroacetophenone is a chemical compound with the molecular formula C8H6BrNO3. It is a yellow crystalline solid that is used in the synthesis of pharmaceutical compounds and organic compounds. This chemical is primarily used as an intermediate in the production of various drugs and organic materials, and it is also utilized in research and development in the pharmaceutical and chemical industries. It is important to handle 2'-bromo-4'-nitroacetophenone with caution, as it is considered to be hazardous and may cause skin and eye irritation upon contact.
Check Digit Verification of cas no
The CAS Registry Mumber 90004-93-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,0,0,0 and 4 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 90004-93:
(7*9)+(6*0)+(5*0)+(4*0)+(3*4)+(2*9)+(1*3)=96
96 % 10 = 6
So 90004-93-6 is a valid CAS Registry Number.
InChI:InChI=1/C8H6BrNO3/c1-5(11)7-3-2-6(10(12)13)4-8(7)9/h2-4H,1H3
90004-93-6Relevant articles and documents
CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS
-
Paragraph 00301, (2013/03/26)
The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
MACROCYCLES AS FACTOR XIA INHIBITORS
-
Page/Page column 141, (2011/09/15)
The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
